Context Therapeutics Stock (NASDAQ:CNTX)
Previous Close
$1.68
52W Range
$0.77 - $2.75
50D Avg
$2.04
200D Avg
$1.83
Market Cap
$123.75M
Avg Vol (3M)
$256.47K
Beta
2.25
Div Yield
-
CNTX Company Profile
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| VECT | VectivBio Holding AG |
| NXTC | NextCure, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ANNX | Annexon, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| WVE | Wave Life Sciences Ltd. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| INAB | IN8bio, Inc. |
| NLTX | Neurogene Inc. |
| CHRS | Coherus BioSciences, Inc. |
| ZURA | Zura Bio Limited |
| AMLX | Amylyx Pharmaceuticals, Inc. |